Overview

Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy

Status:
Terminated
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label, single arm phase 1 study to evaluate the dose-limiting toxicity, maximum tolerated dose, and recommended phase II dose of Clioquinol in patients with relapsed or refractory hematologic malignancies. The study will also characterize Cliquinol's safety, tolerability and pharmacodynamic effect.
Phase:
Phase 1
Details
Lead Sponsor:
University Health Network, Toronto